+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      A single-arm Phase II validation study of preventing oxaliplatin-induced hypersensitivity reactions by dexamethasone: the AVOID trial

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.



          Patients with colorectal cancer treated with oxaliplatin are at risk of hypersensitivity reactions, with the incidence estimated to be 12%–20%. Coinfusion of dexamethasone and oxaliplatin could potentially reduce the incidence of these reactions, but oxaliplatin is reported to be incompatible with alkaline compounds in solution. However, in a previous retrospective study we found that the pH of a solution of dexamethasone and oxaliplatin was less than 7.4, and that hypersensitivity to oxaliplatin could have been prevented by coinfusion of dexamethasone. We aimed to evaluate the effectiveness of coinfusion of dexamethasone and oxaliplatin to prevent oxaliplatin-induced hypersensitivity reactions.

          Patients and methods

          The AVOID trial was a prospective, multicenter, open-label, single-arm Phase II trial conducted from January to September 2013. The study included 73 patients who received capecitabine plus oxaliplatin (XELOX) or XELOX plus bevacizumab therapy for colorectal cancer. In all patients, oxaliplatin was administered in combination with dexamethasone. The primary outcome measure was the presence of hypersensitivity reactions.


          Hypersensitivity reactions occurred in three patients (4.1%); all three experienced a cutaneous reaction (grade 1 erythema). None of the 73 patients developed respiratory symptoms, ocular symptoms, or anaphylaxis. Grade 3 or higher hemotoxicity occurred in 13.7% of the patients and grade 3 or higher nonhematological toxicity occurred in 13.7%. The response rate to treatment was 64.4%.


          The coinfusion of dexamethasone and oxaliplatin effectively reduced oxaliplatin-induced hypersensitivity reactions in patients with colorectal cancer. This approach should be considered for all patients treated with oxaliplatin, allowing treatment to be completed as planned.

          Related collections

          Most cited references 42

          • Record: found
          • Abstract: found
          • Article: not found

          Hypersensitivity to antineoplastic agents: mechanisms and treatment with rapid desensitization.

          Hypersensitivity reactions (HSRs) to chemotherapy drugs, such as taxanes and platins, and to monoclonal antibodies limit their therapeutic use due to the severity of some reactions and the fear of inducing a potentially lethal reaction in highly sensitized patients. Patients who experience hypersensitivity reactions face the prospect of abandoning first-line treatment and switching to a second-line, less effective therapy. Some of these reactions are mast cell-mediated hypersensitivity reactions, a subset of which occur through an immunoglobulin (IgE)-dependent mechanism, and are thus true allergies. Others involve mast cells without a demonstrable IgE mechanism. Whether basophils can participate in these reactions has not been demonstrated. Rapid drug desensitization (RDD) is a procedure that induces temporary tolerance to a drug, allowing a medication allergic patient to receive the optimal agent for his or her disease. Through RDD, patients with IgE and non-IgE HSRs can safely be administered important medications while minimizing or completely inhibiting adverse reactions. Due to the clinical expansion and success of RDD, the molecular mechanisms inducing the temporary tolerization have been investigated and are partially understood, allowing for safer and more effective protocols. This article reviews the current literature on molecular mechanisms of RDD with an emphasis in our recent contributions to this field as well as the indications, methods and outcomes of RDD for taxanes, platins, and monoclonal antibodies.
            • Record: found
            • Abstract: found
            • Article: not found

            Hypersensitivity reactions related to oxaliplatin (OHP)

            Oxaliplatin (OHP) is the most recent platinum compound entering the clinical practice. It is an alkylating agent on DNA and forms DACH-platinum DNA adducts more hydrophobic than those formed by cisplatin (CDDP) and carboplatin (CBDCA). It is effective in advanced colorectal cancer both as a first-line therapy and in 5-fluorouracil (5-FU) refractory patients (Bertheault-Cvitkovic et al, 1996; De Gramont et al, 1997; Andre' et al, 1999; Maindrault-Goebel et al, 1999). OHP is less nephro-ototoxic than CDDP and less mielotoxic than CBDCA (Misset 1998). The most characteristic and dose-limiting toxicity of OHP is sensory neuropathy, which is dose cumulative and schedule related. It is clinically characterised by a transient acute cold-related dysaesthesias, sometimes pain-associated, or with cramps and functional failure, although it is generally reversible (Caussanel et al, 1990, Misset, 1998). Hypersensitivity reactions to oxaliplatin have been described only sporadically. For other platinum compounds, this kind of reaction is well known (Cleare et al, 1976; Wiesenfeld et al, 1979; Planner et al, 1991; Morgan et al, 1994; Weideman et al, 1994; Shleback et al, 1995; Markman et al, 1999; Özgüroglu et al, 1999). On data sheets of OHP, these clinical features are not stressed. In fact, only the main severe form of hypersensitivity, that is to say anaphylaxis, is reported in 0.5% of patients treated. This reaction is clinically characterised by laryngospasm and wheezing and immunologically linked to the release of histamine and other vaso-active substances. As a result of the increasing use of OHP in colorectal cancer, we have found frequent hypersensitivity reactions. In this study, we report the epidemiological and clinical features of these reactions, as well as their management. MATERIALS AND METHODS From February 1999 to February 2002 at the Institute of Haematology and Medical Oncology ‘L. and A. Seragnoli’ of Bologna and at the Medical Oncology Division of Livorno, 124 outpatients with advanced colorectal cancer were treated with OHP-based therapies. Eighty-four out of 124 patients (67.7%) received OHP as a first-line treatment. Fifty-five patients (44.3%) were treated with a FOLFOX-4 regimen (Andre' et al, 1999; De Gramont et al, 2000), 34 patients (27.4%) with FOLFOX-3 regimen (De Gramont et al, 1999), 30 patients (24.1%) with the association of OHP/CPT-11/c.i.5-FU/FA regimen (Falcone et al, 2002), three patients (2.4%) with OHP alone (Diaz-Rubio et al, 1998) and two patients (1.6%) with OHP/Raltitrexed regimen (Seitz et al, 1999). All patients received a standard antiemetic treatment with ondansetron 8 mg by a i.v. administration before chemotherapy. We did not use dexamethasone in this population. Major sites of metastases were the liver, lungs and peritoneum. Among these patients, 17 out of 124 (13.7%) reported a hypersensitivity reaction attributable to OHP. There were eight males and nine female patients, with a mean age of 60.3 years (range 37–76). In 11 out of 17 patients with hypersensitivity reaction, OHP was administered in first-line chemotherapy. RESULTS Results are shown in Table 1 Table 1 Patients with hypersensitivity reactions Case Sites of metastases Chemotherapy regimen Infusion number at reaction Total dose of OHP (mg) Clinical features of reaction Length of reaction (min) Treatment of reaction Re-exposure to OHP with premedication and outcome 1 Lung FOLFOX-4 3 382 Bronchospasm 7 days Hospitalisation/high dose of steroid No           Laryngospasm                 Dyspnoea       2 Peritoneum FOLFOX-4 14 2100 Bronchospasm 60 Oxygen No           Dyspnoea   Steroids             Hand oedema   Antihistaminic             Eriythema       3 Liver Oxaliplatin 10 2070 Bronchospasm 50 Steroids No           Dyspnoea                 Hypotension       4 Liver FOLFOX-3 17 2271 Dyspnoea 5–10 Steroids Yes, with reaction   Lung       Hand, face oedema   Antihistaminic             Erythema, itching                 Psychomotor agitation       5 Peritoneum Oxalipatin 2 360 Dyspnoea 120 Steroids No           Laryngospasm   Antihistaminic   6 Liver Irinotecan 11 1620 Dyspnoea 15–20 Steroids No     Oxaliplatin     Eye oedema   Antihistaminic       Fluorouracil     Face erythema           Folinic acid     Itching                 Sweating       7 Liver FOLFOX-3 17 2720 Dyspnoea 15–20 Steroids Yes, with reaction   Lung       Oedema   Antihistaminic             Erythema                 Sweating                 Lachrymation       8 Liver FOLFOX-4 6 900 Dyspnoea 30 Steroids No           Erythema   Antihistaminic             Itching                 Mouth oedema       9 Liver FOLFOX-4 8 1120 Dyspnoea 60 Steroids No   Lung       Hand, face erythema   Antihistaminic   10 Liver FOLFOX-4 8 1360 Erythema, 15–20 Steroids No           Tachycardia   Antihistaminic             Precordial pain                 Pruritus       11 Peritoneum FOLFOX-4 9 630 Hand oedema, Hand genital itching 20 Antihistaminic Yes, without reaction           Hand, face erythema       12 Peritoneum FOLFOX-4 5 940 Hand face erythema 20–30 Antihistaminic No           Hand oedema                 Hand itching       13 Liver Irinotecan 14 2600 Itching 15–20 Steroids Yes, with reaction   Peritoneum Oxaliplatin     Sweating   Anthistaminic       Fluorouracil     Lachrymation           Folinic acid     Face oedema,                 Face erythema       14 Liver FOLFOX-4 7 1040 Face, chest erythema 120 Steroids Yes, with reaction           Itching   Antihistaminic   15 Liver FOLFOX-4 13 1705 Face, chest erythema 50 Steroids No   Peritoneum       Shiver without fever   Antihistaminic             Tremor       16 Diaphragm FOLFOX-4 8 1080 Arms, chest erythema 50 Steroids Yes, with reaction           With pomphoid reaction       17 Peritoneum FOLFOX-3 9 1377 Sweating 15–20 Steroids No           Erythema                 Hypotension                 Nausea       . The reaction occurs after a mean±s.e.=9.4±1.07 infusions of chemotherapy (range 2–17). Only two patients experienced early hypersensitivity at the second and third infusion, respectively. On average, there were 217.7±32.5 days (mean±s.e.) (range 74–575) between the first exposure to OHP and the reaction. Eight out of 124 (6.5%) patients reported only erythema and itching of the palms and flushing of the face and hands after the beginning of OHP infusion. Nine out of 124 (7.3%) patients developed a more severe reaction with dyspnoea, wheezing, laryngospasm, psico-motor agitation, tachycardia, precordial pain, diffuse erythema, itching and sweating. Only two patients experienced the symptoms at the end of the infusion, while the others developed the reaction between 10 to 15 min from the start of OHP infusion. All patients showing hypersensitivity were treated with steroids, many of them in association with antihistaminic drugs. The symptoms disappeared within half an hour to 2 h after stopping the OHP infusion and the beginning of the antiallergic therapy. One patient required hospitalisation for dyspnoea that disappeared in a few days. Once the reaction had disappeared, nine patients continued the scheduled drug infusions, in particular 5-fluorouracile (5-FU) and Folinic acid, without any additional problem. The percentage of reaction is different according to the chemotherapy regimens employed: 66.6% for OHP alone, 18.1% for FOLFOX-4 regimen, 8.8% for FOLFOX-3 regimen and 6.6% for OHP/CPT-11/c.i.5-FU/FA regimen (Table 2 Table 2 Number of reactions according to the regimen Chemotherapy regimen No. of patients No. of reactions % reaction according to the regimen Mean no. of infusions at the reaction onset FOLFOX-4 55 10 18.1 8.1 FOLFOX-3 34 3 8.8 14.3 Irinotecan Oxaliplatin Fuorouracil Folinic acid 30 2 6.6 12.5 Oxaliplatin 3 2 66.6 6 ). Three patients developed the reaction to the first chemotherapy treatment after a long period of rest. The total administered doses of OHP in patients developing the reaction are reported in Table 1. The cumulative dose of OHP was 1428 mg±176.7 (mean±s.e.) (range 360–2720 mg). Six out of 17 patients with hypersensitivity reactions were successively re-exposed to OHP chemotherapy after premedication with steroids and antihistaminic drugs. Five of these six patients developed the same symptoms again, while one patient had no further reaction. DISCUSSION Hypersensitivity reactions to platinum compounds are a well-known phenomena (Weiss, 1992). In the 1950s, literature reported the capacity of platinum salts to induce bronchial asthma among platinum-refinery workers (Hunter et al, 1945). It is not surprising that after the introduction of platinum compounds into chemotherapy, their association with type I hypersensitivity reactions was confirmed (Cleare et al, 1976). These reactions were first described for CDDP with a 5–20% incidence (Wiesenfeld et al, 1979; Shleback et al, 1995; Özgüroglu et al, 1999), and evidence regarding similar reactions for CBDCA are also available (Planner et al, 1991; Morgan et al, 1994; Weideman et al, 1994; Markman et al, 1999). This kind of toxicity has been sporadically reported in clinical trials focusing on the effectiveness of OHP in chemotherapy or described as case reports (Machover et al, 1996; Diaz Rubio et al, 1998; Tournigand et al, 1998; Larzilliere et al, 1999; Medioni et al, 1999; De Gramont et al, 2000; Dold et al, 2002; Monnet et al, 2002). Our results support the assumption that this side effect should not be underestimated. More than 13% of OHP-treated patients developed hypersensitivity reaction. This phenomenon is not well known, probably because OHP entered clinical practice only a few years ago. Moreover, according to our experience, the reactions generally develop after about 9–10 infusions. The relationship between the hypersensitivity reaction and OHP is supported by the following evidence. First, the symptoms developed a few minutes after starting the OPH infusion; secondly, the patients re-exposed to successive OHP administration developed a similar reaction; thirdly, two patients developed a reaction after monochemotherapy OHP infusion; finally, in patients treated with OHP/CPT-11/c.i. 5-FU/FA regimen, the reaction could be confused with a cholinergic syndrome due to CPT-11, but the responsibility of CPT-11 can be excluded since the re-exposure to CPT-11/c.i. 5-FU/FA without OHP was not able to provoke the hypersensitivity reaction. The pathophysiology of hypersensitivity reactions is not clear, but the finding that almost all patients developed the reaction after multiple infusions of treatment suggests the need to be sensitised during previous cycles. Symptoms usually develop early after the start of the infusion and have been ascribed to a type I hypersensitivity Ig-E-mediated reaction (Stahl et al, 2001). A different hypothesis suggests that platinum salts could induce an oligo or polyclonal T-cells expansion. These compounds can act as a superantigen on the peripheral blood mononuclear cells, thus releasing a large amount of proinflammatory cytokines (IL-6, TNFα, γ interferon) (Santini et al, 2001). The other possible mechanism consists in binding the platinum salts to different peptides of major histocompatibility complex (MHC). In fact, HLA phenotype is a significant determinant of occupational sensitisation to inhaled hapten of complex platinum salts and the strength of this association varies according to the intensity of exposure (Newman Taylor et al, 1999). Furthermore, the relationship between hypersensitivity reactions and HLA-haplotype has been described for other drugs (Hetherington et al, 2002). Additional factors are deemed to be necessary to the immune system for developing the reaction after several infusions. Apart from hypersensitivity-related dyspnoea and wheezing, the lung may also be the target of a particular toxicity. A patient treated with OHP-5FU therapy developed severe dyspnoea. A bronchus alveolar lavage (BAL) and a lung biopsy diagnosed a diffuse alveolar damage that disappeared with steroid therapy (Trisolini et al, 2001). In our experience, when a hypersensitivity reaction occurred, the infusion of OHP was immediately stopped and replaced by a saline infusion, an intravenous antihistaminic drug and a low-dose corticosteroids administration. In the case of more severe reactions (dyspnoea, sweating, bronchospasm, laryngospasm), we immediately administered a high dose of steroid. The steroid dose ranged between 100 and 1000 mg of hydrocortisone. After the reaction disappeared, the OHP infusion was not restarted and the decision to administer the other scheduled drugs was taken evaluating the clinical status of the patient after the reaction, the risk of additional toxicity and the clinical utility of the chemotherapy. In this way, about two-thirds of patients (11 patients) continued the infusion of other planned antiblastic drugs without any additional clinical problems. In order to avoid further hypersensitivity problems in successive cycles, one can presumably explore a maximum prophylactic immunological blockage with a high dose of steroids and antihistaminic drugs for several days before the infusion of OHP, but the real benefit is uncertain because five out of six patients treated with steroids and/or antihistaminic drugs immediately before re-exposure developed the same intensity of reaction. Documented data suggest that OHP as a continuous 6-h infusion seems to decrease the risk of hypersensitivity reactions. Only one out of 100 (1%) patients treated with OHP as a 6-h infusion added to chronomodulated 5-FU–FA as a first-line treatment of advanced colorectal cancer developed hypersensitivity-like reactions (Giacchetti et al, 2000). When OHP is infused in a chronomodulate setting (as a 12-h infusion) or flat infusion for 5 days, these hypersensitivity reactions do not occur. In particular, 151 patients submitted to 1087 constant rate continuous infusion courses of OHP, and 491 patients submitted to 3106 chronomodulate OHP courses did not experience any hypersensitivity reactions (Caussanel et al, 1990; Levi et al, 1992, 1993, 1994b, 1997, 1999; Bertheault-Cvitkovic et al, 1996). Therefore, the incapacity of these schedules to produce hypersensitivity might be due to a long time infusion rather than to failure of activation of the immune system (which presents a circadian rhythm) in a chronomodulate setting (Levi et al, 1994a). Interestingly, five patients who developed hypersensitivity reactions to 2-h OHP infusion, when re-exposed to 6-h OHP infusion, did not show any symptoms (Maindrault-Goebel et al, 2001). The mechanism is still unclear, although it is supposed that the maximum concentration reached by the drug is lower in a longer time of infusion. Theoretically this situation might occur with increased hydration, but no data are available. In the adjuvant setting, the number of allergic reactions is different from the advanced disease. In fact only 2% of the allergic, not already specified, reactions have been reported (De Gramont et al, 2002). The reason for this important difference is unclear. It could be possible that the tumour releases factors able to make the immune system more sensitive, but no data are available. In our study, neither the cumulative dose of OHP nor the lapse of time between the first exposition and the reaction are able to predict the hypersensitivity reaction. In our experience, the severity of clinical symptoms is variable and we cannot identify the patients at risk of developing the reaction or the factors indicating the patients where the reaction could be more severe. Particular attention is necessary when the lung is the target of reaction, because the re-exposure to OHP generally affects the same site with higher intensity. Special care is mandatory in patients receiving OHP for a long time and/or re-exposing to OHP after a pause. In conclusion, a late hypersensitivity reaction seems a limiting toxicity of OHP administered in 2 h, and in patients previously affected it is advisable to avoid readministration of OHP with the same short schedule. Literature data suggest that long-term OHP infusions are able to prevent the hypersensitivity reaction. The use of steroids does not seem useful in preventing hypersensitivity in patients having experienced previous reactions. On the contrary, long-term infusions, without dose decreasing, may prevent this reaction in patients previously affected, but a larger number of cases are required to provide definite responses on this matter.
              • Record: found
              • Abstract: found
              • Article: not found

              Hypersensitivity and idiosyncratic reactions to oxaliplatin.

              Oxaliplatin is a third-generation platinum analog that is used to treat a variety of solid tumors, particularly colorectal carcinoma. Patients may develop hypersensitivity reactions, although this complication occurs infrequently. Three patients developed hypersensitivity reactions to oxaliplatin while undergoing treatment on a Phase I trial of oxaliplatin and capecitabine. An Entrez PUBMED search was performed to identify other cases. Two patients experienced the abrupt onset of erythema alone or with pruritus during the 9th and 11th infusions of oxaliplatin, whereas the other patient developed fever and mild dyspnea a few hours after the 9th oxaliplatin infusion. All 3 patients were rechallenged successfully for at least 1 additional oxaliplatin infusion by using oral dexamethasone, 20 mg orally, 6 and 12 hours before the administration of oxaliplatin and by administering intravenously 125 mg of solumedrol, 50 mg of diphenhydramine, and 50 mg of cimetidine 30 minutes before oxaliplatin. The literature review suggests two distinct patterns of reactions: classic hypersensitivity (as experienced by the first two patients) and idiosyncratic reactions (as experienced by the third patient). Patients who develop mild to moderate hypersensitivity to oxaliplatin may be pretreated with steroids and antagonists of Type 1 and 2 histamine receptors, whereas patients who develop severe reactions are unlikely to tolerate further therapy.

                Author and article information

                Drug Des Devel Ther
                Drug Des Devel Ther
                Drug Design, Development and Therapy
                Drug Design, Development and Therapy
                Dove Medical Press
                11 November 2015
                : 9
                : 6067-6073
                [1 ]Department of Gastroenterological Surgery, Fukuoka University Faculty of Medicine, Fukuoka, Japan
                [2 ]Department of Surgery, Fukuoka Sanno Hospital, Fukuoka, Japan
                [3 ]Department of Surgery, Fujita Health University School of Medicine, Toyoake, Japan
                [4 ]Department of Surgery, Kansai Medical University Hirakata Hospital, Osaka, Japan
                [5 ]Gastrointestinal Cancer Center, Sano Hospital, Kobe, Japan
                [6 ]Department of Surgical Oncology, Kanazawa Medical University, Uchinada, Japan
                [7 ]Academia, Industry and Government Collaborative Research Institute of Translational Medicine for Life Innovation, Fukuoka University, Fukuoka, Japan
                Author notes
                Correspondence: Yoichiro Yoshida, Department of Gastroenterological Surgery, Fukuoka University Faculty of Medicine, 7-45-1 Nanakuma, Jonan-ku, Fukuoka 814-0180, Japan, Tel +81 92 801 1011, Fax +81 92 863 9759, Email yy4160@ 123456yahoo.co.jp
                © 2015 Yoshida et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License

                The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.

                Original Research

                Pharmacology & Pharmaceutical medicine

                allergy, oxaliplatin, dexamethasone, hypersensitivity


                Comment on this article